Seroprevalence and specificity of NMO-IgG (anti-aquaporin 4 antibodies) in patients with neuropsychiatric systemic lupus erythematosus
Language English Country Germany Media print-electronic
Document type Journal Article, Research Support, Non-U.S. Gov't
- MeSH
- Aquaporin 4 analysis blood MeSH
- Biomarkers analysis blood MeSH
- Fluorescent Antibody Technique, Indirect MeSH
- HEK293 Cells MeSH
- Immunoglobulin G analysis blood MeSH
- Comorbidity MeSH
- Humans MeSH
- Prevalence MeSH
- Recombinant Proteins MeSH
- Seroepidemiologic Studies MeSH
- Myelitis, Transverse diagnosis epidemiology immunology MeSH
- Lupus Vasculitis, Central Nervous System diagnosis epidemiology immunology MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Geographicals
- Czech Republic epidemiology MeSH
- Names of Substances
- Aquaporin 4 MeSH
- AQP4 protein, human MeSH Browser
- Biomarkers MeSH
- Immunoglobulin G MeSH
- Recombinant Proteins MeSH
Neuropsychiatric manifestations are present in 30-40% of patients with systemic lupus erythematosus (SLE). Recently, antibodies to aquaporin-4 (termed AQP4-Ab, or NMO-IgG), a water channel protein, were reported to be present in a subset of patients with SLE and neurological involvement. To evaluate the syndrome specificity and prevalence of serum NMO-IgG/anti-AQP4 antibodies in patients with neuropsychiatric systemic lupus erythematosus (NPSLE). Sera of 76 patients with SLE and neurological symptoms, 50 of whom met the ACR case definitions of NPSLE, were tested for AQP4-Ab in an indirect immunofluorescence assay employing HEK293 cells transfected with recombinant human AQP4. Only one of the examined sera was positive for NMO-IgG/AQP4-Ab. This patient suffered from TM, ranging over two vertebral segments on spinal MRI. None of the 75 NPSLE without TM was found to be seropositive for NMO-IgG/AQP4-Ab. NMO-IgG/AQP4-Ab in NPSLE were present only in a patient with TM and were not detectable in NPSLE patients with other neurological manifestations. Testing for NMO-IgG/AQP4-Ab positivity should be considered in patients presenting with SLE and TM. Non-longitudinally extensive lesions do no not exclude NMO-IgG/AQP4-Ab in patients presenting with SLE and TM.
See more in PubMed
Brain. 2007 May;130(Pt 5):1235-43 PubMed
Ann Neurol. 2006 Mar;59(3):566-9 PubMed
Biochem Biophys Res Commun. 2009 Sep 4;386(4):623-7 PubMed
Acta Ophthalmol. 2009 Mar;87(2):204-10 PubMed
Arthritis Rheum. 2010 Apr;62(4):1198-200 PubMed
Lancet. 2004 Dec 11-17;364(9451):2106-12 PubMed
Medicine (Baltimore). 1976 Jul;55(4):323-39 PubMed
Arthritis Rheum. 1982 Nov;25(11):1271-7 PubMed
Neuroscience. 2010 Jul 28;168(4):1009-18 PubMed
J Neurol Sci. 2010 Apr 15;291(1-2):52-6 PubMed
Ann Rheum Dis. 2000 Feb;59(2):120-4 PubMed
J Neurol Sci. 2010 Nov 15;298(1-2):158-62 PubMed
Arthritis Rheum. 2007 Mar 15;57(2):347-51 PubMed
Brain. 2008 Nov;131(Pt 11):3072-80 PubMed
Ann Rheum Dis. 2010 Dec;69(12):2074-82 PubMed
Arthritis Rheum. 1999 Apr;42(4):599-608 PubMed
Brain. 2010 Feb;133(Pt 2):349-61 PubMed
Arch Neurol. 2008 Jan;65(1):78-83 PubMed
Neurology. 2006 May 23;66(10):1485-9 PubMed
